Elevation Oncology, Inc. (ELEV) Stock Analysis & Investment Frameworks
Elevation Oncology, Inc. (ELEV) stock analysis on Invetso. Review Elevation Oncology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Elevation Oncology, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Elevation Oncology, Inc. Key Financial Metrics
- Market Cap: $21.63M
- Revenue: $N/A
- ROE: -77.48%
- ROIC: -49.04%
- Dividend Yield: N/A
About Elevation Oncology, Inc.
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.